SMARCB1 and bladder transitional cell carcinoma: The lowest SMARCB1 levels in the TCGA-BLCA cohort were noted in the subset of tumors that harbored either deep or shallow SMARCB1 deletions (~34% of BLCA tumors) (Fig. 1D).